ITHACA, N.Y. — Investigators at Cornell University’s Ithaca campus and Weill Cornell Medicine will use a three-year, $5.1 million grant to launch an autism-research center.
The National Institutes of Health’s (NIH) Autism Data Science Initiative (ADSI) awarded the grant, per the Cornell Chronicle, the university’s news website.
The new center is officially called the Autism Replication, Validation, and Reproducibility (AR2) Center. It aims to improve the reliability of autism research and foster public trust in the field.
(Sponsored)
4 Steps in IT Offboarding to Protect Data & Minimize Risk
When employees are laid off or let go, the conversation of technology offboarding can be an uncomfortable one. However, cybersecurity and data protection must be a priority. This can alleviate
Keeping Your Firm Secure on the Road to Digitization
By Dan Hernborg Sales Engineer With the looming threat of a potential recession and economic downturn, many professional service firms are looking to reduce costs and increase efficiency in preparation.
“The AR2 Center will serve as a scientific quality control hub for the ADSI teams and projects,” Judy Zhong, the principal investigator who is leading the project, said in the Cornell announcement. Zhong is the chief of the division of biostatistics in the department of population health sciences and director of the data coordinating center at Weill Cornell Medicine.
AR2 is one of 13 projects that the $50 million ADSI research effort is funding to assess the roles of genetics, environmental interactions, and other factors in autism, Cornell said. AR2 will use existing data from previous research, Medicaid claims, and other data repositories, including the INSIGHT Clinical Research Network, and PCORnet, to support its analysis of the validity and generalizability of ADSI results.
Dr. Rainu Kaushal, who leads the INSIGHT Clinical Research Network, is another researcher working with Zhong. Kaushal is senior associate dean of health data science at Weill Cornell Medicine and chair of the department of population health sciences at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center.
Zhong and her colleagues will use a three-step process that starts with replicating the data analysis to confirm the initial results reported by ADSI investigators, Cornell said. Then, they will validate that the investigators’ models work in different subsets of patients or in patients identified using different diagnostic tools. Finally, they will ensure that other scientists can reproduce the findings by providing adequate documentation and transparency.
A community advisory board will meet with the AR2 leaders every six months to advise them and help ensure that the projects addresses the needs of patients and their families.
The board includes policymakers, researchers and parents of children with autism.
“We hope to build and ensure trust in ADSI’s research,” Zhong said. “We want patients and their families to be heard. We hope to serve as a bridge so that the patient community and policy makers can understand the science.”
